"Pharmaco-economic Cost-effective Single-center Prospective Randomized Trial Evaluating the Open Interest Caphosol ® Mouthwashes in the Prevention and Treatment of Severe Oral Mucositis in Patients Receiving High-dose Chemotherapy in Hematology '

• The number of days without medication morphine won [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• Aggregate saving medicines prescribed Supportive [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• - The incidence and severity of mucositis [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• The intensity and duration of pain assessed with a visual analogue scale, [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• The cumulative dose of morphine administered and the number of days of treatment, [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• the incidence and duration of febrile neutropenia [ Time Frame: 28 jours ] [ Designated as safety issue: No ]
• - The incidence and duration of treatment of anti-infective and antifungal [ Time Frame: 28 jours ] [ Designated as safety issue: No ]
• The incidence and duration of total parenteral nutrition, [ Time Frame: 28 jours ] [ Designated as safety issue: No ]
• - The duration of Release aplasia (ANC> 500/mm3), [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• The duration of the hospitalization [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 28 days ] [ Designated as safety issue: No ]

The purpose of the study is to determine whether the use of mouthwashes Caphosol ™ in addition to standard oral care (strategy A) is cost-effective in the prevention and treatment of severe mucositis in adult patients with auto or allograft packaging without ICT versus mouthwashes standard bicarbonates with an antiseptic (strategy B).

• Device: Caphosol

  The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)

  The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.

  Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.

  The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0.

• Drug: Bicarbonate de sodium

  Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.

  Versylène: Method of administration: gargle made ​​with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®.

• Experimental: Caphosol
  Intervention: Device: Caphosol
• Active Comparator: Référence
  •Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
  Intervention: Drug: Bicarbonate de sodium

Inclusion Criteria:

• Patients > 18 years

Patient receiving:

• Conditioning of autologous bone marrow transplantation by high dose melphalan (HD) as part of the management of myeloma or BEAM in lymphoma.
• A conditioning allogeneic bone marrow transplantation with reduced or intermediate busulfan IV
• Patients belong to a schema of social security, having signed the written informed consent.

Exclusion Criteria:

• patients:
• To receive or have received KGF
• With previous history of RT with the exception of patients who received spinal analgesic therapy in the treatment of myeloma
• Unable or unwilling to complete the self assessment questionnaire
• With previous history of allergy to any component of the products under consideration
• Minor
• Adults under guardianship
• Pregnant women
• Patients who have not signed the consent form
• Creation of mouthwash out of the study